Ramucirumab Medicine 09 January 2018 Extended indication Advanced urothelial cancer, second line. Therapeutic value Possible equal value Total cost € 0.00 Registration phase Clinical trials Product Active substance Ramucirumab Domain Oncology and Hematology Reason of inclusion Main indication Bladder cancer Extended indication Advanced urothelial cancer, second line. Current proprietary name Already available biosimilars / generics Proprietary name Cyramza Manufacturer Eli Lilly Portfolio holder Mechanism of action Unknown Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Anti-VEGF receptor 2 antibody. Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Indication extension ATMP Unknown Submission date Expected Registration September 2019 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Sinds kort immunotherapie Therapeutic value Possible equal value This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Median 12 week / weeks Frequency of administration 2 times a month Dosage per administration 10 mg/kg References Petrylak et al. Lancet. 2017 Nov 18;390(10109):2266-2277 Additional remarks Behandelschema: 12 weken/4 toedieningen; 1 maal per 3 weken. Expected patient volume per year Patient volume 0 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks De verwachting is dat met de introductie van immunotherapie deze behandeling niet tot vrijwel niet zal worden voorgeschreven. Expected cost per patient per year Cost € 15,000.00 - 20,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Medicijnkosten.nl Additional remarks Meerkosten. Bij aantal toedieningen van vier; 75 kg gewicht; 10 mg/kg; betekent zes ampullen 10 mg/l van 50 ml: €17.171,94. Potential total cost per year Total cost € 0.00 Total cost for sluice Additional remarks Off label use Off label use No Indications off label use References Additional remarks Indication extension Indication extensions No Indication extensions References Additional remarks Other information Additional remarks